Dec 12, 2022 / 01:30PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics top line data call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Eric McIntyre, Head of Investor Relations. Please go ahead.
Eric McIntyre - Arcutis Biotherapeutics, Inc. - Head of IR
Thank you, Michelle. Good morning, everyone, and thanks for joining. We are incredibly excited to be here with you again today to discuss pivotal Phase III results from our INTEGUMENT-1 and 2 trials in atopic dermatitis and certainly also proud of the continued execution on the clinical front and progress towards realizing the long-term value for topical roflumilast. A couple of logistical details before we get started. Our Arcutis management team is all here today, and will also be joined by Dr. Larry Eichenfield during our prepared remarks as well as for Q&A.
You could find today's webcast and posted presentation under the Events and Presentations section of our Investor website.
Arcutis Biotherapeutics Inc Atopic Dermatitis Topline Data Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers